← Back to patent-cliff list
CAS 90600-20-7
(S,E)-2-((tert-butoxycarbonyl)amino)pent-3-enoic acid(S)-N-Boc-allylglycine
Codes：IXAB-022、ANID-020
Application context (from source-drug indications)
乳腺癌伊沙匹隆转移性乳腺癌伊沙匹隆宫颈癌伊沙匹隆前列腺癌伊沙匹隆实体瘤伊沙匹隆中性粒细胞减少伊沙匹隆念珠菌病阿尼芬净念珠菌血症阿尼芬净真菌感染阿尼芬净腹膜炎阿尼芬净脓肿阿尼芬净呼吸道感染阿尼芬净
Source drugs (routes using this intermediate)
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpropionamide→5-bromopent-1-ene→(S)-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N,2-dimethylhept-6-enamide→(1S,2S)-1-(((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)(methyl)amino)-2-methylhept-6-en-1-ol→(S)-2-methylhept-6-enal→3-((tert-butyldimethylsilyl)oxy)-4,4-dimethyl-5-oxoheptanoic acid→(3S,6R,7S,8S)-3-((tert-butyldimethylsilyl)oxy)-7-hydroxy-4,4,6,8-tetramethyl-5-oxotridec-12-enoic acid→(S,1E,5E)-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-amine→(3S,6R,7S,8S)-3-((tert-butyldimethylsilyl)oxy)-7-hydroxy-4,4,6,8-tetramethyl-N-((S,1E,5E)-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-yl)-5-oxotridec-12-enamide→(4S,7R,8S,9S,16S,Z)-4-((tert-butyldimethylsilyl)oxy)-8-hydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→morpholine→isobutyraldehyde→4-(2-methylprop-1-en-1-yl)morpholine→(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl pentanoate→2,2-dimethyl-3-oxopentanal→allylbis(4,6,6-trimethylbicyclo[3.1.1]hept-2-en-3-yl)borane→tert-butyldimethylsilyl trifluoromethanesulfonate→5-((tert-butyldimethylsilyl)oxy)-4,4-dimethyloct-7-en-3-one→3-((tert-butyldimethylsilyl)oxy)-4,4-dimethyl-5-oxoheptanal→(S,E)-2-aminopent-3-enoic acid→(S,E)-2-((tert-butoxycarbonyl)amino)pent-3-enoic acid→tert-butyl (S,E)-(1-(methoxy(methyl)amino)-1-oxopent-3-en-2-yl)carbamate→tert-butyl (S,E)-(2-oxohept-5-en-3-yl)carbamate→((2-methylthiazol-4-yl)methyl)diphenylphosphine oxide→tert-butyl ((S,1E,5E)-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-yl)carbamate→methoxybis(4,6,6-trimethylbicyclo[3.1.1]hept-2-en-3-yl)borane
(S)-N-Boc-allylglycine→Allylamine→tert-Butyl [(2S)-1-oxo-1-[(prop-2-en-1-yl)amino]pent-4-en-2-yl]carbamate→tert-Butyl [(3S)-2-oxo-1,2,3,4-tetrahydropyridin-3-yl]carbamate→tert-Butyl [(3S,5R,6R)-5,6-dihydroxy-2-oxopiperidin-3-yl]carbamate→(4R,5R)-N2-(tert-Butoxycarbonyl)-4,5-dihydroxy-L-ornithine→(4R,5R)-N2-(tert-Butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-4,5-dihydroxy-L-ornithine→(4R,5R)-4,5-Bis(acetyloxy)-N2-(tert-butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-ornithine→Resin bound (4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-N5-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-ornithine→(3S,4S)-N-Fmoc-3-acetoxy-4-methyl-L-proline→Resin bound N5-[(3S,4S)-3-(acetyloxy)-1-[[(9H-fluoren-9-yl)oxy]carbonyl]-4-methyl-L-prolyl]-(4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine→O-Acetyl-N-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-threonine→Resin bound N5-[O-acetyl-N-[[(9H-fluoren-9-yl)oxy]carbonyl]-L-threonyl-(3S,4S)-3-(acetyloxy)-4-methyl-L-prolyl]-(4R,5R)-4,5-bis(acetyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | (S)-2-((tert-butoxycarbonyl)amino)pent-4-enoic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.